The US Food and Drug Administration has issued a new draft guidance regarding the types of manufacturing changes that can be reported in annual reports.
The US Food and Drug Administration has issued a new draft guidance regarding the types of manufacturing changes that can be reported in annual reports.
The guidance lists 44 postapproval manufacturing changes that may now be reported in annual reports instead of supplements, because the changes are considered to be of low risk to product quality. Examples of these changes include: the elimination or reduction of an overage from the drug product manufacturing batch formula, changes to filtration process parameters, changes in the approved analytical procedure if the revisions do not change the acceptance criteria, and replacement of nonspecific identity tests with discriminating identity tests. The entire list can be found on the FDAs web site.
The draft guidance seeks to reduce the number of CMC manufacturing supplements for NDAs and ANDAs, which have been steadily increasing over the last several years.
This draft guidance also reflects an ongoing shift at the agency toward implementing risk-based approaches to manufacturing quality.
This approach was first outlined in 2002 in the FDA's cGMPs for the 21st Century Initiative, now referred to as the Pharmaceutical Product Quality Initiative, in which the FDA stated that CMC product review should be based on an understanding of product risk and how best to manage that risk with limited agency resources.
Comments on the draft guidance should be submitted by September 23, 2010.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.